COMMUNIQUÉS West-GlobeNewswire
-
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
28/10/2025 -
Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025
28/10/2025 -
KFSHRC inaugure la première usine de fabrication de thérapies géniques et cellulaires en Arabie saoudite
28/10/2025 -
Regeneron Reports Third Quarter 2025 Financial and Operating Results
28/10/2025 -
PL BioScience Announces new Board Member Ole Henrik Bang-Andreasen
28/10/2025 -
Upgrade of guidance
28/10/2025 -
Orion Group Interim Report January–September 2025
28/10/2025 -
Zymeworks Announces Participation in Upcoming Investor Conferences
28/10/2025 -
Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines
28/10/2025 -
Swarm Oncology announces research collaboration with a leading hospital to advance T cell therapies for advanced solid cancers
28/10/2025 -
Novartis announces expiration of Tourmaline Bio tender offer
28/10/2025 -
Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan
28/10/2025 -
Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance
28/10/2025 -
Press release: Sanofi successfully prices USD 3 billion of bond issue
28/10/2025 -
Communiqué de presse : Sanofi place 3 milliards de dollars d’emprunts obligataires
28/10/2025 -
Positive phase III results for Roche’s Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome
28/10/2025 -
Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025
28/10/2025 -
Présentation du tout premier grand modèle de langage multiomique au monde au salon Global Health Exhibition de Riyad, ou la promesse d’un décodage du langage de la biologie humaine
28/10/2025 -
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
27/10/2025
Pages